0001493152-26-031095.txt : 20260629 0001493152-26-031095.hdr.sgml : 20260629 20260629163144 ACCESSION NUMBER: 0001493152-26-031095 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260629 DATE AS OF CHANGE: 20260629 EFFECTIVENESS DATE: 20260629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FibroBiologics, Inc. CENTRAL INDEX KEY: 0001958777 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 863329066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-588997 FILM NUMBER: 261136175 BUSINESS ADDRESS: STREET 1: 9350 KIRBY DRIVE STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 281-671-5150 MAIL ADDRESS: STREET 1: 9350 KIRBY DRIVE STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: FibroBiologics Inc. DATE OF NAME CHANGE: 20221216 D 1 primary_doc.xml X0708 D LIVE 0001958777 FibroBiologics, Inc. 9350 KIRBY DRIVE SUITE 300 HOUSTON TX TEXAS 77054 281-671-5150 DELAWARE FibroBiologics LLC Fibrobiologics, Inc. FibroBiologics Inc. Corporation true 2021 Pete O'Heeron 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer Director Robert Hoffman 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Matthew Link 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Victoria Niklas 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Richard C. Cilento 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Jason D. Davis 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer Chief Financial Officer Pharmaceuticals Decline to Disclose 06b false 2026-06-25 false true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 NY NEW YORK false 3000000 3000000 0 Includes pre-funded warrants ($0.0001 exercise price per share) and Series A and Series B common stock purchase warrants ($0.735 exercise price per share), each exercisable for up to 4,081,663 shares of common stock. false 1 315000 0 Represents a 7% fee; a 1% management fee; reimbursement of non-accountable expenses of $25,000 and legal fees of $50,000; and placement agent warrants to purchase 285,714 shares (exercise price of $0.9188 per share). 0 The issuer intends to use the net proceeds from this offering for working capital and general corporate purposes. false FibroBiologics, Inc. /s/ Ruben A. Garcia Ruben A. Garcia General Counsel 2026-06-29